RecruitingNCT05636709

National GMA Post-market Clinical Follow-up Study (GRACE)

National Post-market Clinical Follow-up Study to Evaluate in Real-world Practice the Efficacy and Safety of Granulocytoapheresis and Its Impact on Quality of Life in Patients With Inflammatory Bowel Disease


Sponsor

Adacyte Therapeutics SL

Enrollment

350 participants

Start Date

Jan 11, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Inflammatory bowel disease (IBD) encompasses several chronic diseases of which ulcerative colitis (UC) and Crohn's disease (CD) are the most representative. IBD is characterised by the presence of an inflammatory process that affects different segments of the digestive tract and has a chronic and relapsing course with flares of activity. Inflammatory activity in IBD is associated with an increase in peripheral blood activated granulocytes and monocyte-macrophages and intestinal infiltration by these inflammatory cells, which are largely responsible for tissue damage. In recent years, observational, prospective studies and meta-analyses of these studies have contributed to consider granulocytapheresis (GMA) as an effective and safe alternative in the treatment of UC. This apheresis technique is based on recirculation of the patient's blood through a circuit with cellulose acetate spheres that perform a selective elimination of granulocytes and monocyte-macrophages leading to a reduction in pro-inflammatory cytokines and adhesion molecule expression, and an increase in anti-inflammatory mediators. These events in the GMA column are followed by other immunological changes, most notably a decrease in CD10+ (activated) neutrophils, leading to a compensation from the bone marrow of a CD10- (immature) neutrophil population. GMA can be considered as a therapeutic alternative in corticodependent IBD, especially in UC. In addition, it can reduce or limit the need for corticosteroids, so another possible application is as a "bridge" treatment in patients starting treatment with thiopurine immunomodulators. A beneficial effect can also be obtained by combining apheresis with biological treatments, especially after a partial response or loss of response to these treatments. Finally, some extraintestinal manifestations associated with IBD may also benefit from its use. The GRACE study is proposed for the evaluation of the efficacy of GMA with Adacolumn® under real conditions of use and according to the indications described in the instructions for use of the medical device.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study follows patients with inflammatory bowel disease (IBD) — either ulcerative colitis (UC) or Crohn's disease — who are receiving granulocyte and monocyte adsorption (GMA) therapy, a blood filtration treatment that reduces inflammation. The study tracks how well the treatment works in real-world clinical practice. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with ulcerative colitis or Crohn's disease - Your doctor has independently decided to start you on GMA therapy - You can understand and sign the informed consent form **You may NOT be eligible if...** - You have a medical or psychological condition that prevents safe participation - You do not consent to the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEAdacolumn

Non interventional study


Locations(30)

H. Albacete

Albacete, Albacete, Spain

H. General de Alicante

Alicante, Alicante, Spain

H. Germans Trias i Pujol

Badalona, Barcelona, Spain

H. Vall d´hebron

Barcelona, Barcelona, Spain

H. Galdakao

Galdakao, Bizkaia, Spain

H. General de Castellón

Castellon, Castellón, Spain

H. Puerta del Mar

Cadiz, Cádiz, Spain

H. Reina Sofía

Córdoba, Córdoba, Spain

H. Donostia

San Sebastián, Gipuzkoa, Spain

H. Virgen de las Nieves

Granada, Granada, Spain

H. Guadalajara

Guadalajara, Guadalajara, Spain

H. San Jorge

Huesca, Huesca, Spain

H. Santiago

Santiago de Compostela, La Coruña, Spain

H. San Pedro

Logroño, La Rioja, Spain

H. Dr. Negrín

Las Palmas de Gran Canaria, Las Palmas de Gran Canarias, Spain

H. 12 de octubre

Madrid, Madrid, Spain

H. La Paz

Madrid, Madrid, Spain

H. Costa del Sol

Marbella, Málaga, Spain

H. Navarra

Pamplona, Navarre, Spain

H. Río Carrión

Palencia, Palencia, Spain

H. Son Espases

Palma de Mallorca, Palma de Mallorca, Spain

H. Son Llatzer

Palma de Mallorca, Palma de Mallorca, Spain

H. Álvaro Cunqueiro

Vigo, Pontevedra, Spain

H. Univ. de Canarias

San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain

H. Ntra. Sra. de Candelaria

Santa Cruz de Tenerife, Santa Cruz de Tenerife, Spain

H. Virgen del Rocío

Seville, Sevilla, Spain

H. Clínico Univ. de Valencia

Valencia, Valencia, Spain

H. General de Valencia

Valencia, Valencia, Spain

H. La Fe

Valencia, Valencia, Spain

H. Virgen de la Concha

Zamora, Zamora, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05636709


Related Trials